Aspirin for primary prevention of coronary heart disease

Area of Science:

• Cardiovascular Medicine
• Preventive Cardiology
• Clinical Pharmacology

Background:

• Coronary heart disease (CHD) remains a leading cause of mortality worldwide.
• Primary prevention strategies aim to reduce the incidence of cardiovascular events in asymptomatic individuals.
• The role of low-dose aspirin in primary prevention is a long-standing clinical question.

Purpose of the Study:

• To systematically review the evidence on the efficacy and safety of aspirin for primary prevention of CHD.
• To assess the impact of aspirin on fatal and non-fatal CHD events.
• To evaluate aspirin's effect on all-cause and cardiovascular mortality.

Main Methods:

• Systematic review and meta-analysis of randomized controlled trials.
• Inclusion of studies involving individuals without symptomatic vascular disease.
• Assessment of both beneficial effects (e.g., reduced events) and harmful effects (e.g., bleeding).

Main Results:

• Analysis of aspirin's net benefit in primary prevention of CHD.
• Evaluation of whether aspirin reduces cardiovascular mortality.
• Investigation into how baseline CHD risk influences aspirin's benefits and harms.

Conclusions:

• The balance of benefits and harms of aspirin in primary prevention requires careful consideration.
• Individualized risk assessment is crucial for guiding aspirin prescribing decisions.
• Further research may be needed to refine recommendations based on varying risk profiles.